Results 11 to 20 of about 13,549 (163)
Carfilzomib-induced Thrombotic Microangiopathy: A Case Based Review
Hematology/Oncology and Stem Cell Therapy, 2023 Carfilzomib is an irreversible proteasome inhibitor currently approved for the treatment of relapsed multiple myeloma. It has been implicated as a cause of thrombotic microangiopathy (TMA) in several case reports.
Nishant Jindal +9 more
doaj +2 more sources
Carfilzomib‐associated pulmonary arterial hypertension in multiple myeloma [PDF]
Pulmonary Circulation, 2021 Drug‐induced pulmonary arterial hypertension (PAH) is constantly evolving as new drugs are developed. Carfilzomib is a recently approved therapy for relapsed and refractory multiple myeloma. While it has been associated with cardiovascular adverse events,
Jenny Z. Yang +3 more
doaj +2 more sources
Sensors, 2021 Carfilzomib is mainly used to treat multiple myeloma. Several side effects have been reported in patients treated with carfilzomib, especially those associated with cardiovascular events, such as hypertension, congestive heart failure, and coronary ...
Thi Thao Mai +7 more
doaj +2 more sources
Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials [PDF]
Blood Advances, 2018 : Carfilzomib is a selective proteasome inhibitor approved for the treatment of relapsed and/or refractory multiple myeloma (RRMM). It has significantly improved outcomes, including overall survival (OS), and shown superiority vs standard treatment with ...
Ajai Chari +13 more
doaj +2 more sources
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021 Background Anticancer therapies have significantly improved patient outcomes; however, cardiac side effects from cancer therapies remain a significant challenge.
Parvin Forghani +11 more
doaj +2 more sources
Taiwanese Journal of Obstetrics & Gynecology, 2016 Objective: Carfilzomib is a second-generation tetrapeptide epoxyketone proteasome inhibitor used in current clinical therapy of hematologic malignancies. The mechanism of proteasome inhibition in endometrial cancer is not very clear.
Yuanyuan Zhou +4 more
doaj +2 more sources
Cardiac and renal complications of carfilzomib in patients with multiple myeloma
Blood Advances, 2017 : Clinical trials with carfilzomib have indicated a low but reproducible incidence of cardiovascular and renal toxicities. Among 60 consecutive myeloma patients treated with carfilzomib-based regimens who were thoroughly evaluated for cardiovascular risk
Meletios A. Dimopoulos +17 more
doaj +3 more sources
Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy [PDF]
Blood Cancer Journal, 2023 Thrombotic microangiopathy (TMA) has been reported to occur in multiple myeloma (MM) patients in association with treatment with carfilzomib, an irreversible proteasome inhibitor (PI).
Maria Moscvin +16 more
doaj +2 more sources
Carfilzomib‐Induced Thrombotic Microangiopathy—Two Case Reports [PDF]
Cancer ReportsBackgroundThrombotic microangiopathy (TMA) is a pathological syndrome characterized by a combination of three key features: microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and organ damage, primarily affecting the kidneys.
Irene Attucci +7 more
doaj +2 more sources
Biomedicines, 2023 Acute liver failure (ALF) is a disease accompanied by severe liver inflammation. No effective therapy is available yet apart from liver transplantation; therefore, developing novel treatments for ALF is urgently required.
Dhafer Y. Alhareth +9 more
doaj +2 more sources